Skip to content
value.today

Flame Biosciences, Inc.

🇺🇸 New York, New York, USABiotechnologyFounded 2017
Total raised
$109 M
2 rounds on record
Latest round
$100 M
Sep 2020
First round on record
Feb 2020
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Flame Biosciences, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Sep 2020$100 MNo. 2$50 to $250 million

Flame Biosciences, Inc.: Raise no. 2, Sep 2020

Investors in this round

40 investors had bought by the notice of Sep 30, 2020: 40 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$100 M of $100 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David Barrett · Executive Officer, Director · Chief Operating Officer, Chief Financial Officer, Secretary and Treasurer
  • George Avgerinos · Executive Officer · Vice President, Manufacturing
  • Harlan Weisman · Executive Officer, Director · President and Chief Executive Officer
  • Robert Stein · Director
  • Tim Opler · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Harlan Weisman, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Sep 30, 2020. Read the notice at the SEC.

equitySEC
Feb 2020$9 MNo. 1$2 to $10 million

Flame Biosciences, Inc.: Raise no. 1, Feb 2020

Investors in this round

58 investors had bought by the notice of Mar 16, 2020: 58 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$9 M of $15 M offered; $6 M still to sell
Smallest investment taken
$25,000
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$712,519
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David Barrett · Executive Officer, Director · Chief Operating Officer, Chief Financial Officer, Secretary and Treasurer
  • George Avgerino · Executive Officer · Vice President, Manufacturing
  • Harlan Weisman · Executive Officer, Director · President and Chief Executive Officer
  • Leonid Gorelik · Executive Officer · Head of Translational Medicine and Research
  • Pamela Demain · Executive Officer · Vice President, Business Development
  • Opler Tim · Director
  • Robert Stein · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • National Securities Corporation (CRD 7569) · broker-dealer Jonathan C. Rich (CRD 2271478) · New York, New YorkSold in all US states

Signed by Harlan Weisman, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Mar 16, 2020. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Flame Biosciences, Inc. chose not to state its revenue in its newest notice of a funding round (Sep 2020).

    SEC Form D · Sep 2020

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Sep 2020

That is all the official record says: Flame Biosciences, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Flame Biosciences, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 58 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Flame Biosciences, Inc.
NameRoleNamed in
David BarrettChief Operating Officer, Chief Financial Officer, Secretary and TreasurerSep 2020
George AvgerinosVice President, ManufacturingSep 2020
Harlan WeismanPresident and Chief Executive OfficerSep 2020
George AvgerinoVice President, ManufacturingMar 2020
Leonid GorelikHead of Translational Medicine and ResearchMar 2020
Pamela DemainVice President, Business DevelopmentMar 2020
David BarrettChief Operating Officer, Chief Financial Officer, Secretary and TreasurerSep 2020
Harlan WeismanPresident and Chief Executive OfficerSep 2020
Robert SteinDirectorSep 2020
Tim OplerDirectorSep 2020
Opler TimDirectorMar 2020